SynAct Pharma AB (SYNACT.ST)
SEK 18.9
(1.83%)
SEK 18.9
(1.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -215.81 Million SEK | -117.54% |
| 2022 | -99.2 Million SEK | -43.14% |
| 2021 | -69.3 Million SEK | -161.02% |
| 2020 | -26.55 Million SEK | -10.82% |
| 2019 | -23.95 Million SEK | -2.19% |
| 2018 | -23.44 Million SEK | -52.29% |
| 2017 | -15.39 Million SEK | 0.39% |
| 2016 | -15.45 Million SEK | -1473.93% |
| 2015 | -982 Thousand SEK | -4.8% |
| 2014 | -937 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -24.9 Million SEK | 72.49% |
| 2024 Q2 | -18.62 Million SEK | 25.21% |
| 2024 Q3 | -20.48 Million SEK | -9.99% |
| 2023 Q2 | -43.51 Million SEK | 12.77% |
| 2023 Q4 | -90.54 Million SEK | -184.03% |
| 2023 Q3 | -31.87 Million SEK | 26.74% |
| 2023 FY | -215.81 Million SEK | -117.54% |
| 2023 Q1 | -49.87 Million SEK | -63.66% |
| 2022 Q2 | -24.75 Million SEK | -23.43% |
| 2022 Q4 | -30.47 Million SEK | -27.42% |
| 2022 FY | -99.2 Million SEK | -43.14% |
| 2022 Q1 | -20.05 Million SEK | 23.48% |
| 2022 Q3 | -23.91 Million SEK | 3.37% |
| 2021 Q4 | -26.21 Million SEK | -43.84% |
| 2021 FY | -69.3 Million SEK | -161.02% |
| 2021 Q3 | -18.22 Million SEK | -38.71% |
| 2021 Q2 | -13.13 Million SEK | -11.96% |
| 2021 Q1 | -11.73 Million SEK | -28.99% |
| 2020 Q3 | -7.6 Million SEK | -57.94% |
| 2020 Q4 | -9.09 Million SEK | -19.61% |
| 2020 FY | -26.55 Million SEK | -10.82% |
| 2020 Q1 | -4.99 Million SEK | 51.86% |
| 2020 Q2 | -4.81 Million SEK | 3.69% |
| 2019 Q2 | -6.36 Million SEK | -62.12% |
| 2019 Q4 | -10.38 Million SEK | -235.28% |
| 2019 FY | -23.95 Million SEK | -2.19% |
| 2019 Q1 | -3.92 Million SEK | 34.64% |
| 2019 Q3 | -3.09 Million SEK | 51.35% |
| 2018 Q3 | -6.54 Million SEK | 16.24% |
| 2018 Q4 | -6 Million SEK | 8.14% |
| 2018 FY | -23.44 Million SEK | -52.29% |
| 2018 Q2 | -7.81 Million SEK | -153.36% |
| 2018 Q1 | -3.08 Million SEK | 46.29% |
| 2017 FY | -15.39 Million SEK | 0.39% |
| 2017 Q1 | -3.39 Million SEK | 56.44% |
| 2017 Q4 | -5.74 Million SEK | -204.74% |
| 2017 Q3 | -1.88 Million SEK | 54.13% |
| 2017 Q2 | -4.1 Million SEK | -21.14% |
| 2016 Q2 | -5.56 Million SEK | 0.0% |
| 2016 Q3 | -2.08 Million SEK | 62.52% |
| 2016 Q4 | -7.78 Million SEK | -272.95% |
| 2016 FY | -15.45 Million SEK | -1473.93% |
| 2015 FY | -982 Thousand SEK | -4.8% |
| 2014 FY | -937 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -1582.336% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 30.595% |
| NextCell Pharma AB | -41.95 Million SEK | -414.325% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -1216.077% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 44.404% |
| AcouSort AB (publ) | -17.08 Million SEK | -1162.859% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1257.125% |
| Xintela AB (publ) | -54.08 Million SEK | -299.035% |
| Ziccum AB (publ) | -21.41 Million SEK | -907.893% |
| Active Biotech AB (publ) | -45.8 Million SEK | -371.201% |
| Alzinova AB (publ) | -16.48 Million SEK | -1209.527% |
| Amniotics AB (publ) | -30.87 Million SEK | -599.093% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 13.185% |
| BioArctic AB (publ) | 229.24 Million SEK | 194.138% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 53.707% |
| Camurus AB (publ) | 431.44 Million SEK | 150.021% |
| Cantargia AB (publ) | -280.02 Million SEK | 22.932% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -923.233% |
| CombiGene AB (publ) | -35.66 Million SEK | -505.096% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -42.121% |
| Genovis AB (publ.) | 61.5 Million SEK | 450.911% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -90.438% |
| Mendus AB (publ) | -101.61 Million SEK | -112.372% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -482.153% |
| Kancera AB (publ) | -64.88 Million SEK | -232.583% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 4106.87% |
| LIDDS AB (publ) | -40.2 Million SEK | -436.761% |
| Lipum AB (publ) | -37.17 Million SEK | -480.478% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -1679.436% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 1873.441% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -1105.845% |
| Saniona AB (publ) | -95.81 Million SEK | -125.248% |
| Simris Alg AB (publ) | -37.3 Million SEK | -478.502% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -20.117% |
| Intervacc AB (publ) | -102.85 Million SEK | -109.826% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -49171.689% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -1206.119% |
| Corline Biomedical AB | -1.8 Million SEK | -11829.795% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -21.351% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -279.807% |
| Aptahem AB (publ) | -11.11 Million SEK | -1841.983% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -75.358% |
| Fluicell AB (publ) | -26.55 Million SEK | -712.721% |
| Biovica International AB (publ) | -124.82 Million SEK | -72.893% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -411.12% |
| Abliva AB (publ) | -95.5 Million SEK | -125.958% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 33.983% |
| 2cureX AB (publ) | -32.51 Million SEK | -563.663% |
| I-Tech AB | 20.2 Million SEK | 1168.208% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 74.053% |
| Cyxone AB (publ) | -22.98 Million SEK | -838.753% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -136.113% |
| Biosergen AB | -27.03 Million SEK | -698.202% |
| Nanologica AB (publ) | -75.15 Million SEK | -187.146% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -389.876% |
| BioInvent International AB (publ) | -330.3 Million SEK | 34.663% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -809.172% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 13.368% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -2073.311% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -97.469% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -1748.005% |